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Background: To evaluate the efficiency of platelet-rich plasma preparations by means of a double centrifugation
tube method to obtain platelet-rich canine plasma at a concentration at least 4 times higher than the baseline
value and a concentration of white blood cells not exceeding twice the reference range. A complete blood count
was carried out for each sample and each concentrate. Whole blood samples were collected from 12 clinically
healthy dogs (consenting blood donors). Blood was processed by a double centrifugation tube method to obtain
platelet concentrates, which were then analyzed by a flow cytometry haematology system for haemogram. Platelet
concentration and white blood cell count were determined in all samples.
Results: Platelet concentration at least 4 times higher than the baseline value and a white blood cell count not
exceeding twice the reference range were obtained respectively in 10 cases out of 12 (83.3%) and 11 cases out of
12 (91.6%).
Conclusions: This double centrifugation tube method is a relatively simple and inexpensive method for obtaining
platelet-rich canine plasma, potentially available for therapeutic use to improve the healing process.
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Growth factors are the conductors or modulators of
wound healing process through induction of chemotaxis,
stimulation of mitosis and upregulation of protein pro-
duction [1-3]. They enhance tissue healing by stimulat-
ing cell proliferation, increasing extracellular matrix
synthesis, and promoting vascular ingrowth [4]. Platelet
concentrates are an important source of autologous GFs
[5]. The platelets α-granules provide a concentrated
source of PDGF, TGFβ and numerous other growth
factors such as VEGF and PDAF, thromboxane and fi-
bronectin/vitronectin [6]. Platelet rich plasma (PRP)
has emerged as an economical method to provide a
source and delivery mode for autologous growth fac-
tors and cell-rich fractions. It has been suggested that
the supraphysiological GFs concentrations present in
this substance could act positively by accelerating
wound healing, decreasing the inflammatory reaction* Correspondence: anna.perazzi@unipd.it
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reproduction in any medium, provided the orand promoting the regeneration rather than repair of
affected tissues [7,8]. Platelet-rich plasma represents
an emerging biotechnology in current tissue engineer-
ing and cellular therapy [9]. It has applications in
management of extensive skin wounds, and in ortho-
paedic diseases, primarily for tendon and ligament repair,
and cartilage resurfacing [6]; its biocompatible and bio-
degradable properties prevent the PRP from inducing for-
eign body reactions, tissue necrosis or extensive fibrosis
[10]. Platelet concentrates can be obtained by means of at
least three general methods: the apheresis, buffy coat, and
tube methods [11]. The apheresis method is performed in
completely closed disposable system: an apheresis unit
was used to obtain platelet concentrate by a process of
discontinuous centrifugation [2]. Setup and processing
times for the apheresis method were longer than for the
buffy coat method. The retail unit and disposables costs
were greater for the apheresis method [2]. Several manu-
facturers provide specific disposable devices, packaged
with syringes, needles and anticoagulant to obtain PRP
using the buffy coat method. The separation of the buffy
coat and plasma uses differential centrifugation and aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the red blood cell mass from the small white blood
cells, platelets and plasma. The platelet-enriched
plasma is concentrated by centrifugation immediately
above the buffy coat layer of white blood cells [6].
The possibility of bacterial contamination of concen-
trates may be greater when using buffy coat methods
rather than apheresis methods [2]. The tube method
has been used for preparing platelet rich plasma; the
advantages of this technique are the low cost and
the minimal technical requirements compared to the
other two general methods described above. How-
ever extreme care should be taken to avoid bacterial
contamination when this technique is performed
[11]. Increasing consent is accumulating that PRP
products must achieve a platelet count of at least
300 × 103 platelets μl-1 to be in the therapeutically
effective range [8,12], indicating approximately a 4–5
times the baseline value [8,9,13-15]. The collective
literature would suggest that platelet concentration
of 4 times is at or near maximal stimulation, and
that leukocyte concentrations should be kept to a mini-
mum to maximize matrix synthesis and minimize
inflammation after PRP injection for the treatment of
injuries [4]. High WBC counts are unacceptable in
blood preparations used for hemotherapy as the re-
sult of increased transfusion reactions, they are gen-
erally accepted in platelet concentrates used for
autologous topical application or as an addictive to a
bone graft. It is a matter of speculation as to whether
they are beneficial or deleterious to wound healing
[2]. The aim of this report is to evaluate the effi-
ciency of PRP preparation using a double centrifuga-
tion tube method, relatively simple and inexpensive,
to obtain a platelet rich plasma with a platelet con-
centration of at least 4 times the baseline value and
a concentration of white blood cells that do not exceed 2
times the reference range.
Methods
Dogs
After obtaining owner consent, twelve clinically healthy
dogs were included in this study. All animals were taken
at the Department of Department of Animal Medicine,
Productions and Health (Faculty of Padua).
Blood collection
Sixteen millilitres of whole blood were taken from each
dog from the cephalic vein using a 21 gauge butterfly
needle and divided into two parts, both collected into
sodium citrate tubes (BD Vacutainer system, Plymoth,
UK).a For each dog a hemogram was performed. The
average time between blood extraction and the start of
sample processing was 20 min.Double centrifugation tube method
Sixteen millilitres of citrated blood were centrifuged
(Labofuge 400, Heraeus Holding, Hanau, Germany)b
without applying a brake for 20 min at 2800 rpm to
achieve separation of cell layers. This procedure divides
the blood into three basic components: red blood cells,
platelet rich plasma (PRP) and platelet poor plasma
(PPP). Red blood cells were isolated from the overlying
buffy coat and plasma by the gel-like plug within the
tubes. From each tube (8 ml of blood) thus yielded
approximately 4–5 mL of platelet-poor plasma, of
which 80% was discarded. The buffy coat of each
tube, containing mononuclear cells and platelets, was then
carefully removed with a pipette and resuspended in
0.75-1.0 mL of the plasma remaining. The final solu-
tion, obtained by mixing different buffy coats in a
sterile 15 ml Falcon tube, was centrifuged without
applying a brake at 1300 rpm for 15 min for good
separation of platelet pellets in the supernatant layer.
The platelet pellet accumulates at the bottom of the
tube, the PPP on top. The PPP is drawn off so that
the PRP remains in the tube. After resuspending the
platelet pellet within the remaining volume of plasma
with the vortex mixer, the final PRP can be drawn up
with a syringe. Each step of the method was carried
out using sterile disposables.
Platelet and leukocyte counts
A complete hemogram was performed for each sam-
ple using a flow cytometry hematology system (ADVIA
120 Analyzer, Bayer Lab, NY, USA).c Both samples
of whole blood and PRP were examined at the end
of the procedure. Hematological parameters analyzed
included: packed cell volume (PCV), platelet count
(PLT), leukocyte count (WBC), as well as the relative
and absolute numbers of neutrophils, lymphocytes,
monocytes, eosinophils, basophils and large unstained
cells (LUC) counts, values for MPV, large platelet
count and platelet clumps (aggregates). For all sam-
ples, a manual blood film examination was performed
in order to confirm the results and evaluate the cell
morphology.
Bacteriological tests
This study was performed using sterile disposables
although laminar flow hood has not been used. The
choice not to use a laminar flow hood is related to
the desire to evaluate the real risk of contamination
to verify the reproducibility of this method even in
structures that are not equipped with such equip-
ment. For each samples bacteriological tests were
carried out in order to verify the level of contamin-
ation on sample of PRP obtained at the end of the
processing.
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All the data obtained were analysed by a commercial
statistical software (SPSS for Windows-Release 12.0.1;
SPSS Inc., IL USA)d. For each measurement of the whole
blood, simulated data were calculated according to the
target of the procedure (i.e. at least 4 concentration
times for platelet count and no more than 2 concentra-
tion times for WBC count). Normality of data was
assessed by one sample Kolmogorov-Smirnov non para-
metric test. The Paired samples t-test was used to com-
pare whole blood, final PRP and simulated PRP groups.
The level of significance was set for p<0.05.
Results and discussion
Twelve clinically healthy half-breed dogs were included
in this study, 6 male and 6 female, aged from 1.5 to 7
years (mean age 3.73 ± 1.74 years). Data for each param-
eter considered of whole blood, platelet rich plasma and
platelet rich plasma simulated are described and summa-
rized in the Table 1; since data are normally distributed,
they are expressed as mean ± standard deviation.
It is important to note that in the platelet rich plasma
the concentration of red blood cells is almost negligible
and that 88 ± 5% of white blood cells is represented by
lymphocytes. In platelet rich plasma was obtained a
mean value of platelet’s concentration of 1981 ± 114
cells × 103/μl. One of the aims set by the authors was to
obtain a platelet’s concentration at least 4 times the
baseline value. This target was achieved in 10 out of 12
dogs (83.3% of the sample); in the other 2 samples the
platelet’s concentration is respectively 3.69 and 3.91
times the baseline value. The cytometric count of plate-
let is significantly different, from the whole blood, in
platelet rich plasma but not in the platelet rich plasma
simulated, as evidenced by boxplots below (Figure 1).
Furthermore, in platelet rich plasma was obtained a mean
value of WBC’s concentration of 14.82 ± 6.57 cells ×
103/μl. The other aim set by the authors was to obtain a
WBC’s concentration no more than 2 concentration
times the baseline value. This target was achieved in 11
out of 12 dogs (91.6% of the sample); in the other sam-
ple the WBC’s concentration is 2.08 times the baseline
value. The cytometric count of WBC in platelet rich
plasma was not significantly different from whole blood;Table 1 Descriptive results of study variables (data presented
Variables Whole blood
(mean +/− SD)
Red blood cells (cells × 106/μl) 5.72 ± 0.62
Lymphocytes (cells × 103/μl) 3.72 ± 0.81
White blood cells (cells × 103/μl) 12.35 ± 2.45a
Platelets (cells × 103/μl) 394 ± 18a
NA = Not available. a,b,cLetters: significant differences between groups (one-sided pthey both differ from the platelet rich plasma simulated,
as evidenced by boxplots below (Figure 2).
The first tube method protocol for preparing human
PCs intended for alveolar-maxillary reconstruction was
originally described by Anitua [11]. There are many pa-
pers trying to characterize and classify the numerous
techniques available on the market in terms of prepar-
ation (centrifugation speed and use of anticoagulant),
content (platelets, leucocytes, and growth factors), and
applications. Currently, all these aspects are strongly
discussed in the literature, and there is no consensus
[16]. There is no evidence of standardization of PRP
preparation and use [16] but common clinically available
materials for blood preparations combined with a two-
step low force centrifugations, to ensure cellular compo-
nent integrity, provided good platelet preparations [17].
In human medicine, the centrifugation steps should be
as delicate as possible but allowing a clean separation of
the blood components. Performing two successive low
force centrifugations can contribute to platelet preserva-
tion [17]. Other author described a protocol based on
two successive centrifugations to obtain highly concen-
trated platelets from whole blood: a first spin, also called
soft spin, separates plasma, buffy coat (containing plate-
lets), and red blood cells and a second spin or hard spin,
further concentrates platelets [16]. The human tube cen-
trifugation protocols are different from the canine tube
technique described here since the effect of sedimenta-
tion on canine platelets is different from the same effect
on human platelets [18]. High centrifugation forces can
lead to activation of platelets during the preparation and
thus impair or diminish platelet function and activity on
the wound directly [17]. However, as well described from
Clemmons, when the size difference between platelets
and RBCs is greater, separation on PRP at high gravita-
tional force resulted in a good platelet yield both with
short or long centrifugation time [18].
Our method involves a double centrifugation: a first
hard spin separates plasma, buffy coat (containing PRP),
and red blood cells and a second soft spin optimizes
platelet concentration without damaging the cells; this
method provides the time of centrifugation of the blood
that will produce an appropriate enrichment of platelets




plasma (mean +/− SD)
0.11 ± 0.06 NA
12.87 ± 5.26 NA
14.82 ± 6.57a 24.69 ± 4.89b
1981 ± 114b 1575 ± 718.5c
<0.05).
Figure 1 Boxplots for platelet cytometric count of whole blood, PRP and simulated PRP groups. a,b,cLetters: significant differences
between groups (one-sided p<0.05). See Table 1 for descriptive data.
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nical inconveniences that are related to the platelet acti-
vation during platelet concentrates preparation. The
platelet activation in fact can contribute to the develop-
ment of platelet storage lesions and decrease platelet
viability. It is therefore important to develop a method to
minimize platelet activation during the preparation of
platelet concentrates [19]. As described by Segawa in 2012
the addition of prostaglandin E1 (PGE1) in PRP be-
fore the centrifugation of PRP can improve the prep-
aration efficiency of platelet concentrates from dogs,
while maintaining the therapeutic efficacy of the
platelets [19]. It would be interesting to evaluate the
method here described in another group of dogs
studying whether the addition of PGE improve the
yield and effectiveness of platelets reducing the per-
centage of activation. Marx [8] postulated that the
ideal platelet concentrate preparation method should
be simple and easy to perform, with the platelets eas-
ily separated from the red blood cells and sequestered
in high concentrations without suffering damage so
that they can actively secrete their growth factors.
The method here described is proved to be quick
(about 90 minutes) and simple to be performed and
does not require particularly expensive equipment. It
is also an easily applicable method in clinical routine.The technique does not require highly qualified staff
to run it in an optimal way. As reported by other au-
thors, more simplified PRP preparation methods
which do not require ad hoc and costly equipment
would help in accumulating clinical data and in intro-
ducing the method more routinely in clinical practice
as also in the operating room [17]. The tube method
presents some technical inconveniences that are related to
the risk of bacterial contamination during the preparation
of platelet concentrate. It is recommended to use a lam-
inar flow chamber and to have trained sanitary personnel
to prepare the platelet concentrate especially when canine
platelet concentrates will be used therapeutically [20].
However this would made the technique accessible only
by laboratories with this equipment. In our study it has
not been possible to work commonly using a laminar flow
chamber, but during all phases of production the
personnel have worked, dressed in lab coats, headgear,
mask and sterile gloves, using sterile disposables on wash-
able surfaces appropriately disinfected. For each sample
bacteriological tests were carried out in order to verify the
level of contamination on sample of PRP obtained at the
end of the processing. Samples of PRP resulted sterile on
bacteriological tests in 11 cases out of 12 (91.67%). In one
sample were found 3 colonies of coagulase-positive
Staphylococcus; this level of contamination should be
Figure 2 Boxplots for WBC cytometric count of whole blood, PRP and simulated PRP groups. a,bLetters: significant differences between
groups (one-sided p<0.05). See Table 1 for descriptive data.
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this method ideal for using the platelet concentrate for
therapeutic purposes in regions that do not necessarily re-
quire a close asepsis, such as the oral cavity, skin and eye.
Given the excellent results we obtained in terms of steril-
ity of the samples, to use this technique for therapeutic
purposes in regions that require a close asepsis it may be
sufficient to perform first a bacterial culture on the plate-
let rich plasma sample obtained to use the product with a
greater safety margin. Increasing consent is accumulating
that PRP products must achieve a platelet count of at least
300 × 103 platelets μl-1 to be in the therapeutically effect-
ive range [8,12], indicating approximately a 4–5 times the
baseline value [8,9,13-15]. In our study a platelet concen-
tration of at least 4 times the baseline was obtained in 10
out of 12 dogs (83.3% of cases). In the remaining 2 sam-
ples the platelet’s concentration is respectively 3.69 and
3.91 times the baseline value: these values are still very
close to the target set by the study. Moreover in absolute
terms, the PRPs of these 2 subjects contained a concentra-
tion of platelets greater than 300 × 103 platelets μl-1
(respectively 1725 × 103 and 1763 × 103 platelets μl-1).
The collective literature would suggest that leukocyte con-
centrations should be kept to a minimum to maximize
matrix synthesis and minimize inflammation after PRP in-
jection for the treatment of injuries [4]. In the samples ofplatelet rich plasma, white blood cells count lower than 2
times the reference range was obtained in 11 out of 12
dogs (91.6% of cases). The real role of the leukocytes
present in human or animal platelet concentrates pre-
pared for tissue healing has never been clarified very well
and their true effect is completely unknown [16]. It should
be considered, for example, that when equine platelet con-
centrate was injected intra-articularly in horses with
severe joint diseases [20], joint effusion and inflammation
were observed during the first days of post treatment.
These clinical effects could be explained by the chemotac-
tic effect of the leucocytes present in high concentrations
in that platelet concentrate. There is a still speculation on
the effect of leukocytes [7] in the PRP used to stimulate
healing. Leukocytes greater than those of the blood are
generally acceptable in autologous platelet concentrates
[21,22]. In human medicine the transfusion of platelet
concentrates are used primarily in homologous transfu-
sion therapy of patients with severe thrombocytopenia
and/or platelet’s disorders. It is known that such transfu-
sion may cause side effects caused by leukocytes that
remain in such preparations such as immunization-HLA,
refractoriness to platelet transfusion reactions, febrile non-
haemolytic transfusion or other complications [21,23]. For
the prevention of such complications, in human medicine
it has been proposed for several years, to transfuse platelets
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to ensure whether the action of white blood cells is benefi-
cial or not to tissue repair [6,25]. A high number of
leucocytes could produce an inflammatory response in cer-
tain tissues, such as articular tissue. Fortier recommends
choosing a PRP with a high concentration of platelets and
a low concentration of leukocytes, so as to maximize anti-
inflammatory effects of TGF-β and reduce catabolism [4].
The influence of leukocytes on the biology of each product
and its potential benefits in term of healing tissue should
be analyzed in more detail in order to explain the many
controversial data of literature [25].
Conclusion
In conclusion, the double centrifugation tube method may
represent a relatively simple and inexpensive method for
obtaining canine platelet rich plasma potentially available
for therapeutic use. Our method has to be evaluated on a
higher number of samples, but the positive preliminary re-
sults achieved suggest this technique might effective and
easily applicable. The procedure can be standardized and
is easy to adapt in clinical settings with minimal infra-
structure, thus enabling large numbers of subjects to
benefit from a form of cellular therapy.
Availability of supporting data
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cluded within the article.
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